Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2022 10:00 ET | Source: Nykode Therapeutics

Nykode Therapeutics to announce financial results for the third quarter 2022 and host webcast presentation on November 23, 2022

OSLO, Norway, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
November 07, 2022 10:30 ET | Source: Nykode Therapeutics

Nykode Therapeutics presents additional efficacy analysis in Phase 2 study of VB10.16 in combination with atezolizumab in advanced cervical cancer

OSLO, Norway, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
November 07, 2022 02:00 ET | Source: Nykode Therapeutics

Nykode Therapeutics to present at two upcoming investor conferences in November

OSLO, Norway, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
October 26, 2022 10:30 ET | Source: Nykode Therapeutics

Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit

VB10.NEO induced a T cell response in 95% of the patients, including expansion of both novel and pre-existing T cells The responses were broad, and the majority of the encoded neoepitopes were...
September 27, 2022 00:45 ET | Source: Nykode Therapeutics

Nykode Therapeutics Announces Positive Results from the Phase 1/2 Open Label, Dose Escalation Trial of its T Cell Focused SARS-CoV-2 Vaccine Candidate

Nykode’s vaccine candidate boosted Spike-specific T cell responses and induced de novo T cell responses to non-Spike antigens found across SARS-CoV-2 variantsNykode’s Vaccibody technology combined...
September 09, 2022 11:00 ET | Source: Nykode Therapeutics

Nykode Therapeutics to present at H.C. Wainwright 24th Annual Global Investment Conference

OSLO, Norway, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
August 22, 2022 00:45 ET | Source: Nykode Therapeutics

Nykode Therapeutics to announce financial results for the first half of 2022 and host webcast presentation on August 24, 2022

OSLO, Norway, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies,...
June 16, 2022 03:00 ET | Source: Nykode Therapeutics

Nykode Therapeutics uplisted to the main list of the Oslo Stock Exchange

OSLO, Norway, June 16, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics ASA (Oslo Stock Exchange (OSE): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of...
June 01, 2022 02:00 ET | Source: Nykode Therapeutics

Nykode Therapeutics to Present at Jefferies Healthcare Conference

OSLO, Norway, June 01, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of...
May 09, 2022 00:45 ET | Source: Nykode Therapeutics

Nykode Therapeutics announces positive interim results from its Phase 2 trial with VB10.16 in combination with immune checkpoint inhibitor atezolizumab in advanced cervical cancer

VB10.16 in combination with atezolizumab demonstrated an ORR of 21%, including 2 CRs and 6 PRs, in a heavily pre-treated population of patients with HPV16-positive advanced cervical cancer VB10.16 in...